NRX Pharmaceuticals' Q1 Revenue Plummets to $1.07M, Missing $25.57M Projection
NRXP has more than doubled off its 52-week low of $1.62 on elevated volume (2.4× avg).
Summary
NRX Pharmaceuticals reported first-quarter 2026 revenue of $1.07 million, a substantial miss compared to the company's own projection of $25.57 million issued just three days prior. The company also posted a net loss of ($1.43 million) and diluted EPS of ($0.04). This significant revenue shortfall, following a recent positive FDA clearance for a key drug candidate, creates a major disconnect for investors. The drastic difference between projected and actual revenue is highly material and will likely trigger a strong negative market reaction, raising concerns about the company's financial transparency and operational performance, especially given its prior "going concern" warning. Investors will now focus on management's explanation for this discrepancy and the path to achieving future revenue growth from recent acquisitions and clinic expansions.
At the time of this announcement, NRXP was trading at $3.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $108.5M. The 52-week trading range was $1.62 to $3.84. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.